Press Releases
iCAD Showcases New ProFound Cloud, Enhanced ProFound Detection Workstation Features and New Strategic Partnerships at SBI Annual Symposium
NASHUA, N.H., April 11, 2024 — iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will showcase its ProFound Breast Health Suite of AI solutions, including the newly released ProFound Cloud, powered by Google Cloud and Google Health AI architecture, while also…
iCAD and Densitas Partner to Enhance Precision Breast Health with Leading AI Solutions for Mammography Quality, Cancer Detection, and Risk Evaluation
NASHUA, NH, and HALIFAX, NS, April 9, 2024 — iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced a strategic partnership with Densitas, Inc., a global leader in operational AI solutions for breast cancer screening. The partnership enables breast imaging centers and radiologists to…
iCAD’s ProFound AI Suite Uncovers Hidden Heart Disease Risk According to New Data Presented at American College of Cardiology Meeting
Study confirms iCAD’s Breast Arterial Calcification AI Algorithm successfully detects calcification of breast vessels, an indicator of cardiovascular disease, from mammograms NASHUA, N.H. – April 8, 2024 – iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today that new data indicates its AI-powered…
iCAD Partners with RAD-AID to Advance Breast Cancer Detection Using AI in Underserved Regions and Low- and Middle-Income Countries (LMICs)
iCAD implements ProFound AI Detection to improve mammography reading and breast cancer detection in low-resource institutions and medically underserved communities. NASHUA, N.H., April 3, 2024 — iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, is proud to announce a philanthropic global health collaboration with…
iCAD Unveils ProFound Cloud, Enabling Interoperability and Access to Breast AI Solutions at Enterprise Scale
ProFound Cloud redefines accessibility to critical insights, empowering radiologists in early breast cancer detection NASHUA, N.H. – April 2, 2024 – iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered cancer detection solutions, today announced commercial availability of ProFound Cloud. The innovative Software-as-a-Service (SaaS) platform provides medical providers…
iCAD Releases Enhanced ProFound Detection Workstation Features to Streamline Mammogram Interpretation for Radiologists
Newly released capabilities — limiting the number of marks on a 3D view, color-coding lesion marks, and color-coding the ProFound Scorecard — enhance radiologists’ interpretability and efficiency NASHUA, N.H. – March 19, 2024 – iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered solutions that enable medical providers…
iCAD Announces Fiscal Fourth Quarter and Full-Year 2023
Annual Recurring Revenue of $8.7 million, an increase of 15% year-over-year Full-Year Operating Cash Flow ($5) million vs. ($12.8) million prior year Year ending cash balance of $21.7M NASHUA, N.H. – March 12, 2024 – iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered solutions that enable medical…
iCAD Highlights Promising Clinical Data Demonstrating Ability to Reduce Breast Interval Cancer Rates and Decrease Recall Rates at ECR 2024; Showcases Additional Platform Offerings
NASHUA, N.H. – Feb. 28, 2024 – iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, will highlight scientific presentations, including an award-winning poster at the European Congress of Radiology (ECR) annual…
iCAD to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
NASHUA, NH., February 27, 2024 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, announced today the Company will release financial results for the fourth quarter and full year…
iCAD expands Board of Directors with the appointment of Dr. Hedvig Hricak, MD, PhD, Dr.h.cm
Dr. Hricak offers extensive experience in radiology, real world application of AI enabled imaging solutions, research, and global healthcare perspectives. NASHUA, NH., February 27, 2024 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD) a global leader in providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect…